167 related articles for article (PubMed ID: 19013265)
1. In vitro and in vivo evidence for stimulation of bone resorption by an EP4 receptor agonist and basic fibroblast growth factor: Implications for their efficacy as bone anabolic agents.
Downey ME; Holliday LS; Aguirre JI; Wronski TJ
Bone; 2009 Feb; 44(2):266-74. PubMed ID: 19013265
[TBL] [Abstract][Full Text] [Related]
2. Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats.
Aguirre JI; Leal ME; Rivera MF; Vanegas SM; Jorgensen M; Wronski TJ
J Bone Miner Res; 2007 Jun; 22(6):877-88. PubMed ID: 17352655
[TBL] [Abstract][Full Text] [Related]
3. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
Tomita M; Li X; Okada Y; Woodiel FN; Young RN; Pilbeam CC; Raisz LG
Bone; 2002 Jan; 30(1):159-63. PubMed ID: 11792579
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone.
Kato N; Kitahara K; Rittling SR; Nakashima K; Denhardt DT; Kurosawa H; Ezura Y; Noda M
J Endocrinol; 2007 Apr; 193(1):171-82. PubMed ID: 17400814
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of prostaglandin E(2)-specific receptor 4 antagonist inhibits lipopolysaccharide-induced osteoclastogenesis in rat periodontal tissue.
Oka H; Miyauchi M; Furusho H; Nishihara T; Takata T
J Periodontol; 2012 Apr; 83(4):506-13. PubMed ID: 21910594
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats.
Iwaniec UT; Moore K; Rivera MF; Myers SE; Vanegas SM; Wronski TJ
Osteoporos Int; 2007 Mar; 18(3):351-62. PubMed ID: 17120182
[TBL] [Abstract][Full Text] [Related]
7. The selective prostaglandin EP4 agonist, APS-999 Na, induces follicular growth and maturation in the rat ovary.
El-Nefiawy N; Abdel-Hakim K; Kanayama N
Eur J Endocrinol; 2005 Feb; 152(2):315-23. PubMed ID: 15745941
[TBL] [Abstract][Full Text] [Related]
8. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone.
Okada Y; Montero A; Zhang X; Sobue T; Lorenzo J; Doetschman T; Coffin JD; Hurley MM
J Biol Chem; 2003 Jun; 278(23):21258-66. PubMed ID: 12665515
[TBL] [Abstract][Full Text] [Related]
9. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
10. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures.
Minamizaki T; Yoshiko Y; Kozai K; Aubin JE; Maeda N
Bone; 2009 Jun; 44(6):1177-85. PubMed ID: 19233324
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Hu S; Liu CC; Chen G; Willett T; Young RN; Grynpas MD
Osteoporos Int; 2016 Feb; 27(2):797-808. PubMed ID: 26272313
[TBL] [Abstract][Full Text] [Related]
12. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.
Liu CC; Hu S; Chen G; Georgiou J; Arns S; Kumar NS; Young RN; Grynpas MD
J Bone Miner Res; 2015 Apr; 30(4):670-80. PubMed ID: 25284325
[TBL] [Abstract][Full Text] [Related]
13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin influences the bone resorption activity of osteoclasts.
Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
Int J Mol Med; 2013 Jun; 31(6):1411-7. PubMed ID: 23563320
[TBL] [Abstract][Full Text] [Related]
15. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
16. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.
Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H
Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.
Kang JH; Ko HM; Moon JS; Yoo HI; Jung JY; Kim MS; Koh JT; Kim WJ; Kim SH
J Dent Res; 2014 Nov; 93(11):1116-23. PubMed ID: 25256714
[TBL] [Abstract][Full Text] [Related]
19. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
Sasaki T
Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416
[TBL] [Abstract][Full Text] [Related]
20. Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways.
Kim BJ; Lee YS; Lee SY; Park SY; Dieplinger H; Yea K; Lee SH; Koh JM; Kim GS
J Endocrinol Invest; 2013 Nov; 36(10):876-82. PubMed ID: 23698732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
